CLIC-INNOVATION
27.8.2024 13:08:28 CEST | Business Wire | Press release
Rare earth elements and rare magnets play a crucial role in advancing the green energy transition and achieving the goals of the European Green Deal. While the EU currently relies heavily on imports from a few countries— with approximately 90% of REEs* coming from outside the EU—this presents an opportunity to develop European expertise and forge strategic partnerships in rare earth metals processing. Strengthening these capabilities within Europe is key to reaching our ambitious targets. Additionally, while challenges remain in REEs recycling, with current rates being less than 5% and some extraction processes needing sustainability improvements, these challenges also present a significant potential for innovation and growth. As demand for REEs increases, driven by their use in electric vehicles, wind turbine motors, and electrolysers for clean hydrogen, there is a tremendous opportunity to enhance recycling efforts and establish more sustainable extraction processes within the EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827785891/en/
CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets (Copyright (c) 2024 Phawat/Shutterstock)
Project targets and development areas
REMHub will develop, test and pilot novel technologies for the exploration and primary production of rare earth elements and for recovering them from side streams to enhance supply security of REEs and rare magnets in the EU. In addition, the project will develop Re-X (Recycle, Reuse, refurbishment and repurposing) technologies for rare earths and valuable metals from end-of-life products as well as electric machine design for easier permanent magnet recycling. The project will also identify and engage relevant stakeholders to develop REE value chains in the EU. The innovation hub will ensure that the novel technologies developed in the project will be commercialized and offered as services via digital platform in the future.
The project’s multi-stakeholder communication and dissemination efforts are designed to actively involve and engage the public and various stakeholders, fostering trust and raising awareness about the importance of REEs. These activities also aim to build essential capacities within the EU. The hub focuses on transformative material sourcing for REEs and REE magnets, including innovations in traceability, digital twinning, and digital passports. Our project partners span the entire REE value chain, from mineral exploration and processing to metal production, magnet manufacturing, and recycling.
The project is committed to a safe and sustainable by design (SSbD) framework, embracing a Re-X approach that prioritizes recycling, reuse, refurbishment, and repurposing, while integrating features for easy dismantling and circularity. REMHub is set to significantly enhance the security of REE supply in the EU. With the support of our digital innovation hub, it will accelerate the development of technologies and services, enabling faster and easier market entry. By the conclusion of the project, future organizations will find it much easier to access sustainably developed REE expert services within the EU.
Project in a nutshell
The project will commence at the beginning of October and last for four years. The project consortium consists of 24 partners from six countries: Finland, Estonia, Spain, Ireland, Slovenia, and Italy. The project preparation and consortium coordination were led by the Finnish organization CLIC Innovation, which also serves as the project coordinator. The estimated total volume of the project is 18 million euros, of which 16 million euros is EU funding. The EU Horizon "resilient value chains" funding instrument supports European sustainable development value chain projects with financing from the European Commission.
* source: https://scrreen.eu/wp-content/uploads/2023/08/SCRREEN2_factsheets_REE-EUROSTAT.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827785891/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
